Oct 5 (Reuters) - Animas Corp, Johnson & Johnson's diabetes care unit, said it intends to exit the insulin pump business due to increased competition and has selected rival Medtronic Plc as its partner for the device.
Nearly 90,000 patients using Animas' pumps will be offered the option to transfer to pumps made by Medtronic, the company said.
Animas said it has discontinued the sale of all Animas Vibe and OneTouch Ping insulin pumps in the United States and Canada, effective immediately.
In January, Johnson & Johnson said it was reviewing strategic options, including the possible sale of some of its diabetes care businesses.
Animas said on Thursday its parent continues to evaluate potential strategic options for blood glucose monitoring business, LifeScan Inc. (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Arun Koyyur)